UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data

Schizophrenia research, 2012-05, Vol.137 (1), p.147-150

2012

Volltextzugriff (PDF)

Bitopertin in negative symptoms of schizophrenia—Results from the phase III FlashLyte and DayLyte studies

Biological psychiatry (1969), 2017-07, Vol.82 (1), p.8-16

2017

Volltextzugriff (PDF)

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms

Psychiatry research, 2014-08, Vol.218 (1), p.219-224

2014

Volltextzugriff (PDF)

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme

The Lancet. Psychiatry, 2016-12, Vol.3 (12), p.1115-1128

2016

Volltextzugriff (PDF)

Psychometric evaluation of the Work Readiness Questionnaire in schizophrenia

CNS spectrums, 2016-04, Vol.21 (2), p.199-206

2016

Volltextzugriff (PDF)

Validity and utility of the PANSS negative symptoms factor score as a clinical trial outcome

Schizophrenia research, 2014, Vol.158 (1), p.e4-e4

2014

Volltextzugriff (PDF)

Quantifying motivational deficits and apathy: A review of the literature

European neuropsychopharmacology, 2015-08, Vol.25 (8), p.1060-1081

2015

Volltextzugriff (PDF)

Pharmacological approaches to treating negative symptoms: A review of clinical trials

Schizophrenia research, 2013-11, Vol.150 (2), p.346-352

2013

Volltextzugriff (PDF)

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

JAMA psychiatry (Chicago, Ill.), 2014-06, Vol.71 (6), p.637

2014

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Study Investigating the Nicotinic [alpha]7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2014-06, Vol.39 (7), p.1568

2014

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2014-06, Vol.39 (7), p.1568-1577

2014

Volltextzugriff (PDF)

Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials

Journal of geriatric psychiatry and neurology, 2015-09, Vol.28 (3), p.159-173

2015

Volltextzugriff (PDF)

Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders

Journal of affective disorders, 2014-10, Vol.168, p.439-451

2014

Volltextzugriff (PDF)

Pharmacological approaches to treating negative symptoms: A review of clinical trials : Negative Symptoms

Schizophrenia research, 2013, Vol.150 (2-3), p.346-352

2013

Volltextzugriff (PDF)

Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms

Schizophrenia research, 2015-03, Vol.162 (1), p.169-174

2015

Volltextzugriff (PDF)

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

Schizophrenia research, 2013-11, Vol.150 (2), p.328-333

2013

Volltextzugriff (PDF)

Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study

Schizophrenia research, 2014, Vol.158 (1), p.e1-e1

2014

Volltextzugriff (PDF)

Identifying clinically relevant milestone decline in predementia Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P155-P156

2015

Volltextzugriff (PDF)

O1‐10‐05: Identifying clinically relevant milestone decline in predementia Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_3), p.P155-P156

2015

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Study Investigating the Nicotinic alpha 7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2014-06, Vol.39 (7), p.1568-1577

2014

Volltextzugriff (PDF)

CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD

Neurobiology of aging, 2016-03, Vol.39, p.S28-S29

2016

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF ADJUNCTIVE BITOPERTIN VERSUS PLACEBO IN SUBJECTS WITH PERSISTENT PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS – UPDATE FROM THE SEARCHLYTE PROGRAMME

Schizophrenia research, 2014-04, Vol.153, p.S20-S20

2014

Volltextzugriff (PDF)

Poster #184 EVALUATING READINESS FOR WORK AND USEFUL ACTIVITIES IN PATIENTS WITH SCHIZOPHRENIA: “THE READINESS FOR WORK QUESTIONNAIRE” WORQ

Schizophrenia research, 2012-04, Vol.136, p.S252-S252

2012

Volltextzugriff (PDF)

Poster #231 EVALUATING READINESS FOR WORK IN PATIENTS WITH SCHIZOPHRENIA: “THE READINESS FOR WORK QUESTIONNAIRE” WORQ

Schizophrenia research, 2012-04, Vol.136, p.S364-S364

2012

Volltextzugriff (PDF)

DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_7), p.P331-P332

2015

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(46)
Buchkapitel
(2)

Sprache

Englisch
(48)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(21)
Humans
(20)
Psychiatry
(19)
Schizophrenia
(13)
Female
(11)
Male
(11)
Adult
(9)
Antipsychotic Agents - Therapeutic Use
(9)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Middle Aged
(8)
Neurosciences & Neurology
(8)
Schizophrenia - Drug Therapy
(8)
Adult And Adolescent Clinical Studies
(6)
Neurology
(6)
Psychology. Psychoanalysis. Psychiatry
(6)
Psychopathology. Psychiatry
(6)
Treatment Outcome
(6)
Clinical Neurology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data

Bitopertin in negative symptoms of schizophrenia—Results from the phase III FlashLyte and DayLyte studies

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms

Psychometric evaluation of the Work Readiness Questionnaire in schizophrenia

Validity and utility of the PANSS negative symptoms factor score as a clinical trial outcome

Quantifying motivational deficits and apathy: A review of the literature

Pharmacological approaches to treating negative symptoms: A review of clinical trials

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

A Randomized, Placebo-Controlled Study Investigating the Nicotinic [alpha]7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials

Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders

Pharmacological approaches to treating negative symptoms: A review of clinical trials : Negative Symptoms

Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study

Identifying clinically relevant milestone decline in predementia Alzheimer's disease

O1‐10‐05: Identifying clinically relevant milestone decline in predementia Alzheimer's disease

A Randomized, Placebo-Controlled Study Investigating the Nicotinic alpha 7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD

EFFICACY AND SAFETY OF ADJUNCTIVE BITOPERTIN VERSUS PLACEBO IN SUBJECTS WITH PERSISTENT PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS – UPDATE FROM THE SEARCHLYTE PROGRAMME

Poster #184 EVALUATING READINESS FOR WORK AND USEFUL ACTIVITIES IN PATIENTS WITH SCHIZOPHRENIA: “THE READINESS FOR WORK QUESTIONNAIRE” WORQ

Poster #231 EVALUATING READINESS FOR WORK IN PATIENTS WITH SCHIZOPHRENIA: “THE READINESS FOR WORK QUESTIONNAIRE” WORQ

DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial

Suchergebnisse filtern